{"product_id":"tirzepatide-30mg-vial","title":"Tirzepatide 30mg Vial - HD LABS","description":"\u003cp data-end=\"620\" data-start=\"440\"\u003eTirzepatide is a peptide studied extensively for its activity across key metabolic and incretin pathways. It functions as a \u003cstrong data-end=\"608\" data-start=\"583\"\u003edual receptor agonist\u003c\/strong\u003e, acting on:\u003c\/p\u003e\n\u003cul data-end=\"736\" data-start=\"622\"\u003e\n\u003cli data-end=\"669\" data-start=\"622\"\u003e\n\u003cp data-end=\"669\" data-start=\"624\"\u003e\u003cstrong data-end=\"669\" data-start=\"624\"\u003eGLP-1 (glucagon-like peptide-1) receptors\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"736\" data-start=\"670\"\u003e\n\u003cp data-end=\"736\" data-start=\"672\"\u003e\u003cstrong data-end=\"736\" data-start=\"672\"\u003eGIP (glucose-dependent insulinotropic polypeptide) receptors\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"939\" data-start=\"738\"\u003eThrough this dual mechanism, tirzepatide has been investigated for its effects on insulin secretion, regulation of hepatic glucose production, delayed gastric emptying, and appetite-related signalling.\u003c\/p\u003e\n\u003cp data-end=\"1136\" data-start=\"941\"\u003eThis product is supplied as a \u003cstrong data-end=\"1005\" data-start=\"971\"\u003e30 mg lyophilised peptide vial\u003c\/strong\u003e, intended for purchasers who have independently researched the compound and are operating under appropriate professional guidance.\u003c\/p\u003e\n\u003chr data-end=\"1141\" data-start=\"1138\"\u003e\n\u003ch3 data-end=\"1182\" data-start=\"1143\"\u003eClinical Trial Evidence (Phase 3)\u003c\/h3\u003e\n\u003cp data-end=\"1279\" data-start=\"1183\"\u003eTirzepatide has undergone extensive \u003cstrong data-end=\"1250\" data-start=\"1219\"\u003ePhase 3 clinical evaluation\u003c\/strong\u003e in large, controlled trials.\u003c\/p\u003e\n\u003cul data-end=\"1735\" data-start=\"1281\"\u003e\n\u003cli data-end=\"1563\" data-start=\"1281\"\u003e\n\u003cp data-end=\"1563\" data-start=\"1283\"\u003eIn Phase 3 studies conducted under controlled conditions, tirzepatide demonstrated \u003cstrong data-end=\"1421\" data-start=\"1366\"\u003esubstantial and sustained reductions in body weight\u003c\/strong\u003e, with participants achieving \u003cstrong data-end=\"1524\" data-start=\"1451\"\u003eaverage weight reductions of up to approximately 22–23% over 72 weeks\u003c\/strong\u003e, depending on dose and study protocol.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1735\" data-start=\"1564\"\u003e\n\u003cp data-end=\"1735\" data-start=\"1566\"\u003ePhase 3 programmes also evaluated long-term safety, tolerability, and metabolic outcomes, forming the basis for subsequent regulatory approvals in certain jurisdictions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1882\" data-start=\"1737\"\u003eOutcomes observed in clinical trials are dependent on controlled protocols and \u003cstrong data-end=\"1881\" data-start=\"1816\"\u003edo not guarantee similar results outside of clinical settings\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-end=\"1887\" data-start=\"1884\"\u003e\n\u003ch3 data-end=\"1919\" data-start=\"1889\"\u003eHow Tirzepatide Compares\u003c\/h3\u003e\n\u003cp data-end=\"1991\" data-start=\"1920\"\u003eTirzepatide is often discussed alongside other incretin-based peptides:\u003c\/p\u003e\n\u003cul data-end=\"2233\" data-start=\"1993\"\u003e\n\u003cli data-end=\"2057\" data-start=\"1993\"\u003e\n\u003cp data-end=\"2057\" data-start=\"1995\"\u003e\u003cstrong data-end=\"2010\" data-start=\"1995\"\u003eSemaglutide\u003c\/strong\u003e functions as a \u003cstrong data-end=\"2057\" data-start=\"2026\"\u003eGLP-1 receptor agonist only\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2141\" data-start=\"2058\"\u003e\n\u003cp data-end=\"2141\" data-start=\"2060\"\u003e\u003cstrong data-end=\"2075\" data-start=\"2060\"\u003eTirzepatide\u003c\/strong\u003e is a \u003cstrong data-end=\"2097\" data-start=\"2081\"\u003edual agonist\u003c\/strong\u003e, targeting both \u003cstrong data-end=\"2141\" data-start=\"2114\"\u003eGLP-1 and GIP receptors\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2233\" data-start=\"2142\"\u003e\n\u003cp data-end=\"2233\" data-start=\"2144\"\u003eThis dual activity differentiates tirzepatide from earlier single-pathway GLP-1 compounds\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"2238\" data-start=\"2235\"\u003e\n\u003ch3 data-end=\"2267\" data-start=\"2240\"\u003eImportant Information\u003c\/h3\u003e\n\u003cul data-end=\"2628\" data-start=\"2268\"\u003e\n\u003cli data-end=\"2314\" data-start=\"2268\"\u003e\n\u003cp data-end=\"2314\" data-start=\"2270\"\u003eSupplied in \u003cstrong data-end=\"2312\" data-start=\"2282\"\u003elyophilised peptide format\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2377\" data-start=\"2315\"\u003e\n\u003cp data-end=\"2377\" data-start=\"2317\"\u003eRequires reconstitution \u003cbr\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2551\" data-start=\"2448\"\u003e\n\u003cp data-end=\"2551\" data-start=\"2450\"\u003eConsultation with a \u003cstrong data-end=\"2502\" data-start=\"2470\"\u003elicensed healthcare provider\u003c\/strong\u003e is essential prior to any consideration of use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2628\" data-start=\"2552\"\u003e\n\u003cp data-end=\"2628\" data-start=\"2554\"\u003eClinical trial results may not reflect individual or real-world outcomes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"2633\" data-start=\"2630\"\u003e\n\u003ch3 data-end=\"2670\" data-start=\"2635\"\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003cp data-end=\"2777\" data-start=\"2671\"\u003eThis product is supplied strictly on an \u003cstrong data-end=\"2739\" data-start=\"2711\"\u003einformed purchaser basis\u003c\/strong\u003e. By purchasing, you acknowledge that:\u003c\/p\u003e\n\u003cul data-end=\"3207\" data-start=\"2779\"\u003e\n\u003cli data-end=\"2854\" data-start=\"2779\"\u003e\n\u003cp data-end=\"2854\" data-start=\"2781\"\u003eYou have independently researched tirzepatide and its regulatory status\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2948\" data-start=\"2855\"\u003e\n\u003cp data-end=\"2948\" data-start=\"2857\"\u003eYou have consulted, or will consult, a qualified healthcare professional prior to any use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3035\" data-start=\"2949\"\u003e\n\u003cp data-end=\"3035\" data-start=\"2951\"\u003eYou understand that clinical trial outcomes do not constitute guarantees of effect\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3121\" data-start=\"3036\"\u003e\n\u003cp data-end=\"3121\" data-start=\"3038\"\u003eThe seller provides \u003cstrong data-end=\"3119\" data-start=\"3058\"\u003eno medical advice, dosing guidance, or therapeutic claims\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3207\" data-start=\"3122\"\u003e\n\u003cp data-end=\"3207\" data-start=\"3124\"\u003eThe \u003cstrong data-end=\"3207\" data-start=\"3128\"\u003eonus of lawful, safe, and appropriate use rests entirely with the purchaser\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"3300\" data-start=\"3209\"\u003e \u003c\/p\u003e","brand":"LIFE.OS","offers":[{"title":"Default Title","offer_id":52824511349054,"sku":"HDTIRZ30MGVIAL","price":1750.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0970\/9826\/8990\/files\/Tirz_30.png?v=1771134908","url":"https:\/\/life-os.co.za\/products\/tirzepatide-30mg-vial","provider":"LIFE.OS","version":"1.0","type":"link"}